CommercialCoverageMedium impact
08.02.26, Nogapendekin alfa inbakicept-pmln (Anktiva®)
Independence Blue Cross·Pharmacy, Oncology·Pharmacy
Effective date
Apr 21, 2025
We identified it
Jun 19, 2026
Summary
This is a new pharmacy policy for Nogapendekin alfa inbakicept-pmln (Anktiva®), a novel immunotherapy agent. The policy establishes coverage criteria, prior authorization requirements, and billing guidelines for this new medication effective April 21, 2025. Billing teams must implement coverage determination processes and prior authorization workflows immediately.
Action Required
By April 21, 2025: Billing team must obtain the full policy document from the source URL to identify specific HCPCS codes (likely J-codes for this biologic therapy) and implement prior authorization requirements in the billing system. Update provider communication to include new prior auth submission requirements for Anktiva® claims. Pharmacy and clinical staff should review coverage criteria and patient eligibility requirements. Without implementation, claims for this medication will be denied or rejected. Contact the insurance carrier if specific billing codes and authorization forms are not included in the full policy text.